JNJ's volume is close to 2x its ADV for 2nd trading day on a roll, but the stock is still holding above its support at the $64 level.<g>
stockcharts.com
JNJ announced record sales of $16B for the 4thQ, an increase of 16.6% vs. 2006. US sales were up 9.1%,& international sales 25.8%.
Earnings for the Q were $2.4B ($.82/shr.)
Sales benefit from strong performance of RISPERDAL CONSTA, INVEGA, TOPAMAX, REMICADE, VELCADE, CONCERTA, & LEVAQUIN., Sales of PROCRIT were lower.
JNJ said that its pipeline has several new drug applications submitted for approval, includeding:
Paliperidone palmitate in the U.S. for the treatment of schizophrenia;
Ustekinumab (CNTO 1275) in the U.S. & Europe, a new, human monoclonal antibody for the treatment of adult patients with chronic to moderate to severe plaque psoriasis;
Dapoxetine in Europe for the treatment of premature ejaculation in men 18-64 years of age;
VELCADE in Europe for the treatment of patients with previously
untreated MM; &
PREZISTA in the U.S. for the treatment of HIV in adult patients with no previous antiretroviral treatment.
In Jan 2008, it received accelerated approval from the FDA for INTELENCE tablets, an anti-HIV medication.
The stock is trading around 4.8xBV with a +CF around $4.60 The short ratio came up almost 10% & is close to 2x its ADV.
The stock needs to close above the resistance at $67.50 & above $70 to make a 3Yrs. H <g>
bigcharts.marketwatch.com
Bernard |
